Clinical Trial

Single Dose Trial of VMX-C001 in Healthy Subjects with and Without FXa Direct Oral Anticoagulant

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A single centre, double-blind, randomized, placebo-controlled single dose study to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of VMX-C001, conducted in two parts: Part 1: Single dose of VMX-C001 or placebo in healthy volunteers. Part 2: Single dose of VMX-C001 or placebo in combination with a selected factor 10a (FXa) direct oral anticoagulant (DOAC) in healthy older subjects.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-04-15; most recent amendment 2024-11-13.
Status change: Recruiting → Active, Not Recruiting 2024-07-19
Trial Details
NCT Number NCT06372483
Lead Sponsor VarmX B.V.
Conditions Coagulation Disorder
Enrollment 40 participants
Start Date 2024-02-21
Primary Completion 2024-08-07 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2024-11-18